Veledimex (S enantiomer)

Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5[1].

Product Specifications

CAS Number

[1093131-03-3]

Product Name Alternative

INXN-1001 (S enantiomer) ; RG-115932 (S enantiomer)

UNSPSC

12352005

Target

Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Veledimex_S_enantiomer.html

Purity

98.17

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NN(C(C1=CC(C)=CC(C)=C1)=O)[C@H](C(C)(C)C)CCC)C2=CC=CC(OC)=C2CC

Molecular Formula

C27H38N2O3

Molecular Weight

438.60

References & Citations

[1]Barrett JA, et al. Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma. Cancer Gene Ther. 2018;25 (5-6) :106-116.|[2]John A. Barrett, INTRATUMORAL REGULATED EXPRESSION OF IL-12 AS A GENE THERAPY APPROACH TO TREATMENT OF GLIOMA. Neuro Oncol. 2015 Nov; 17 (Suppl 5) : v113.